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Otterbein University, Westerville, Ohio
Introduction
Providing patient care in the
operating room as a nurse anesthetist is
rewarding and challenging. There is a
paramount level of responsibility that
lies on certified registered nurse
anesthetist (CRNA). Recognition of
serious life threatening conditions by
CRNA must be prompt and treated
urgently. As a student registered nurse
anesthetist and future CRNA, knowing
how to recognize and treat developed
emergency conditions while patient is
under anesthesia or recovering from
anesthesia is an absolute requirement.
Malignant hyperthermia (MH), is a rare
autosomal dominant hypermetabolic
“potentially fatal disorder of skeletal
muscles” (Riazi, & Brandom, 2015).
Malignant hyperthermia is caused by
volatile anesthetics (desflurane,
sevoflurane, isoflurane) or depolarizing
muscle relaxant (succinylcholine).
Incidence of MH varies between
1/50,000 to 1/250,000 and highest in
young population with average age of
18.3 years upon exposure to volatile
anesthetics or succinylcholine and is
associated with 23 genetic mutations
(Nagelhout & Plaus, 2014).
In contrast, according to Malignant
Hyperthermia Association of United
States (MHAUS, 2015) MH arises
1/100,000 in adults and 1/30,000 in
children during exposure to triggering
agent. Mitchell-Brown (2012) reports
that there are more than 80 genetic
defects associated with MH. The two
gene mutations directly associated with
MH susceptibility are RYR1 and
CACNA1S (Rosenberg, Pollock,
Schiemann, Bulger, & Stowell, 2015).
However, another study states that only
1% of MH cases due to CACNA1S gene
on chromosome 1q32, and MH
susceptibility due to mutation of the
RYR1 gene found on chromosome
19q13.1 (Salazar, Yang, Shen, Abdullah,
& Kim, 2014). Wisconsin, Nebraska,
West Virginia, and Michigan are states
with most MH occurrences. MH has
higher prevalence among men versus
women, even though it is autosomal
dominant disorder.
Upon exposure, MH susceptible
individuals could progress to potentially
fatal hypermetabolic crisis which occurs
shortly after induction of anesthesia
(Cain, Riess, Gettrust, & Novalija, 2014).
MH is known to happen in post
anesthesia care unit (PACU) or any

location where patient is recovering
from general anesthesia during which
volatile anesthetics or succinylcholine
were used (Cain et al., 2014). MH could
also be triggered by stressors alone such
as excessive exercise and heat
(Rosenberg et al., 2015). In order to
provide lifesaving intervention for
patient who is experiencing MH, it is
imperative to understand
pathophysiology, signs and symptoms,
management and treatment, and the
importance of thorough preoperative
patient assessment for prevention of MH
occurrence (Nagelhout & Plaus, 2014).
Untreated MH could lead to multiple
organ failure and death (Seifert, Wahr,
Pace, Cochrane, & Bagnola, 2014).

Significance of Pathophysiology

Pathophysiology

MH is rare but potentially fatal skeletal muscle disorder which requires prompt
intervention to decrease mortality rate. In the initial years of MH discovery, mortality rate
due to MH disorder was 80%. In recent years, this number has changed to approximately
5%, and is contributed to increased education and awareness among healthcare providers,
early recognition and prompt administration of dantrolene sodium to stop MH crisis
(Mitchell-Brown, 2012). Dantrolene inhibits calcium release by inhibiting RYR receptor at
postsynaptic dendrite (Bandschapp & Gerard, 2012). Multiple shared signs and symptoms
with other disorders, variable penetrance and absence of phenotypical characteristics in
the absence of triggering agent and variable onset after administration of triggering agent
makes it difficult to timely identify MH crisis and implement timely intervention.
Understanding pathophysiology of MH could lead to early recognition and intervention
and better outcomes for patients experiencing MH crisis.

Shresta, 2013

The RYR1-ryanodine receptor controls
calcium release from sarcoplasmic
reticulum (skeletal muscle) and is one of the
main defects for MH susceptible individuals,
however 40-50% of MH susceptible
individuals have no associated defect in
RYR1 receptor (Riazi, & Brandom, 2015).
MH susceptibility linked to calcium release
defect in skeletal muscle; no established
linkage to calcium release flaw in cardiac or
-Variable onset of one to 36 hours of
smooth muscle cells (Mitchell-Brown, 2012).
administration of volatile anesthetic or
In MH susceptible patients, volatile
succinylcholine (Mitchell-Brown, 2012).
anesthetics and/or depolarizing muscle
-Early clinical signs:
relaxant causes a defect in calcium
Hypercapnia, with rise in EtCO2
regulation, leading to increased myoplasmic
with normal patient ventilation (indicating calcium levels. Excess calcium release
underlying hypermetabolism) and
causes uncoupling of oxidative
increased end-tidal carbon dioxide
phosphorylation and increased metabolic
(ETCO2) refractory to increased
rate (Marino & Sutin, 2014). Excess
ventilation or additional administration of myoplasmic calcium levels cause sustained
anesthetic
actin-myosin interaction (muscle
Masseter muscle spasm
contraction) which causes muscle rigidity,
Tachycardia without explanation
increased body temperature, increased
(Seifert et al., 2014).
production of carbon dioxide, and increased
-Cardinal symptoms: rigidity, muscle
oxygen consumption (Riazi, & Brandom,
breakdown (rhabdomyolysis; causing
2015). ATP dependent calcium reuptake
increase CK and myoglobin), respiratory
mechanism attempts to stabilize calcium
acidosis, temperature increase, cardiac
levels in myoplasm, thus increasing muscle
involvement, and “other indicators of
metabolism. Accelerated cellular
metabolic derangement not part of a single metabolism requires increased oxygen
process” (Heytens, Forget, Scholtès, &
uptake and causes increased carbon dioxide
Veyckemans, 2015).
level, heat production while using all
Labile blood pressures, skim mottling,
available ATP, causing elevated lactic acid.
cyanosis.
Acidosis, hypethermia and ATP depletion
-Late clinical signs: Hyperthermia
leads to sarcolemma damage. Elevated
body core temperature may rise at a rate
levels of potassium (due to cell death and
of 1ºC to 2ºC every 5 minutes with average released potassium from the cell into blood
of 39.3ºC or 102.7ºF, with temperature
stream), myoglobin (rhabdomyolysis, due to
rising above 43.3 ºC (110ºF).
death of muscle cells), and creatinine kinase
Acidosis, hyperkalemia and hyperthermia secreted into extracellular fluid (Nagelhout
causes cardiac irritability, arrhythmias and & Plaus, 2014). Elevated potassium levels,
could lead to cardiac arrest. Death from
above 6 meq/L may lead to fatal
MH is typically due to cardiovascular
dysrhythmias; myglobin released into
collapse (Mitchell-Brown, 2012).
bloodstream causes precipitate formation in
Laboratory results typically show
renal tubules, leading to acute kidney injury
byproducts of muscle breakdown such as
(Mitchell-Brown, 2012). If no intervention
myoglobinuria (dark colored urine),
implemented to stop excess calcium release,
hyperkalemia, and elevated creatinine
MH progression leads to left ventricular
kinase level. Arterial blood gas shows
dysfunction due to hypertension, pulmonary
mixed metabolic and respiratory acidosis. edema and disseminated intravascular
coagulation (DIC) (Mitchell-Brown, 2012).

Implications for Nursing Care

-At first suspicion of MH, discontinue inhalation agent, call MH hotline

Signs and Symptoms

Retrieved from: http://flipper.diff.org/app/items/info/5018

Ryanodex, a new dantrolene formulation. (2016). Retrieved from:
http://www.slideshare.net/merdonius1/ryanodexa-newdantrolene-formulation

Please Call MH Hotline at:
1-800-644-9737
Be prepared to give your name, number, facility and
email, in the event the call is dropped
(outside of the US: 209-417-3722 ) and
view our Managing an MH Crisis Page. (MHAUS, 2015)

-Hyperventilate with 100% oxygen at high flows (10L/min) to improve
tissue oxygenation, eliminate CO2.
-Administer dantrolene 2.5mg/kg IV bolus and repeat as necessary every 510 minutes until symptoms subside. If total dose greater than 20 mg/kg of
dantrolene administered without improvement, reconsider diagnosis. 20
-mg vial of dantrolene must be reconstituted with 60 ml of sterile water for
injection. Additional medical personnel must be utilized to reconstitute
dantrolene with sterile water, since it is time consuming.
-Initiate cooling by lavage, chilled IV normal saline, surface cooling.
Patient’s temperature should be kept under 38.5ºC (Bandschapp & Girard,
2012)
-Do not administer calcium channel blockers with dantrolene.
-Obtain ABG, electrolytes, glucose every 15 minutes. Correct metabolic
acidosis with sodium bicarbonate 1-2 meq/kg, based on pH and base
deficit. -Obtaine coagulation profile, CK, blood and urine myoglobin, liver
enzyme levels.
-Treat hyperkalemia with hyperventilation, bicarbonate and intravenous
insulin and glucose.
-Maintain urine output greater than 2ml/kg/hr with hydration, lasix (0.5-1
mg/kg) and mannitol as needed. Invasive hemodynamic monitoring should
be established (Nagelhout & Plaus, 2014).

Conclusion
Retrieved from:
http://hyperthermiaponimal.blogspot.com/2015/06/treatmentprotocol-for-malignant.html

Schneiderbanger, Johannsen, Roewer, & Schuster,
2014.

Malignant hyperthermia is a rare, autosomal dominant disorder and
medical emergency that requires immediate recognition and treatment
in order to increase patient’s chances of survival. It has variable
penetrance and is typically triggered by volatile anesthetics and/or
depolarizing muscle relaxant (succinylcholine). CRNAs must perform a
very thorough pre-operative assessment to detect any indications of
patient’s MH susceptibility. Operating room personnel must be familiar
with signs and symptoms of MH, especially early signs of MH in order to
implement timely MH protocol treatment. CRNAs, operating room
nurses and ICU nurses must be educated on MH treatment and
management for best possible patient outcome.
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